Literature DB >> 23873431

Sporadic late onset nemaline myopathy and immunoglobulin deposition disease.

Kathrin Doppler1, Stefan Knop, Hermann Einsele, Claudia Sommer, Carsten Wessig.   

Abstract

INTRODUCTION: In monoclonal gammopathy, organ dysfunction can occur due to deposition of immunoglobulin fragments. A rare form of acquired myopathy often associated with monoclonal gammopathy is sporadic late onset nemaline myopathy (SLONM), which is characterized by nemaline rods in myofibers. The pathogenetic link between monoclonal gammopathy and SLONM has not yet been elucidated.
METHODS: Case report of a patient with monoclonal gammopathy who developed a progressive myopathy, finally diagnosed as SLONM.
RESULTS: A muscle biopsy showed mild myopathic changes. A second biopsy 1 year after clinical onset demonstrated deposition of immunoglobulin light and heavy chains and the presence of nemaline rods. The patient experienced marked improvement of muscle strength after autologous stem cell transplantation and treatment with bortezomib, a therapy that is known to be effective in light chain deposition disease.
CONCLUSIONS: We speculate that deposition of light and heavy chains, rather than nemaline bodies, has myotoxic effects on skeletal muscle.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  bortezomib; immunoglobulin deposition; light and heavy chain deposition disease; muscle biopsy; sporadic late onset nemaline myopathy (SLONM)

Mesh:

Substances:

Year:  2013        PMID: 23873431     DOI: 10.1002/mus.23954

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  6 in total

1.  Sporadic late-onset nemaline myopathy: clinical, pathology and imaging findings in a single center cohort.

Authors:  Mauro Monforte; Guido Primiano; Gabriella Silvestri; Massimiliano Mirabella; Marco Luigetti; Cristina Cuccagna; Enzo Ricci; Serenella Servidei; Giorgio Tasca
Journal:  J Neurol       Date:  2018-01-22       Impact factor: 4.849

2.  Clinicopathologic Profiles of Sporadic Late-Onset Nemaline Myopathy: Practical Importance of Anti-α-Actinin Immunostaining.

Authors:  Bing Zhao; Tingjun Dai; Dandan Zhao; Xiaotian Ma; Cuiping Zhao; Ling Li; Yuan Sun; Yongqing Zhang; Yaping Yan; Jian-Qiang Lu; Fuchen Liu; Chuanzhu Yan
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-05-17

Review 3.  Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 cases.

Authors:  Lukas J Schnitzler; Tobias Schreckenbach; Aleksandra Nadaj-Pakleza; Werner Stenzel; Elisabeth J Rushing; Philip Van Damme; Andreas Ferbert; Susanne Petri; Christian Hartmann; Antje Bornemann; Andreas Meisel; Jens A Petersen; Thomas Tousseyn; Dietmar R Thal; Jens Reimann; Peter De Jonghe; Jean-Jacques Martin; Peter Y Van den Bergh; Jörg B Schulz; Joachim Weis; Kristl G Claeys
Journal:  Orphanet J Rare Dis       Date:  2017-05-11       Impact factor: 4.123

4.  Chemotherapy with stem cell transplantation is more effective than immunotherapy in sporadic late onset nemaline myopathy with monoclonal gammopathy.

Authors:  Rouslan Kotchetkov; Anna Dyszkiewicz-Korpanty; Vishal Kukreti
Journal:  Bone Marrow Transplant       Date:  2018-01-24       Impact factor: 5.483

5.  Impact of hematologic complete response in the treatment of sporadic late-onset nemaline myopathy associated with monoclonal gammopathy.

Authors:  Tânia Maia; Rui Bergantim; Henrique Costa; Jorge Pinheiro; Fernanda Trigo
Journal:  Clin Case Rep       Date:  2021-07-16

6.  Inflammatory features in sporadic late-onset nemaline myopathy are independent from monoclonal gammopathy.

Authors:  Jantima Tanboon; Akinori Uruha; Yukie Arahata; Carsten Dittmayer; Leonille Schweizer; Hans-Hilmar Goebel; Ichizo Nishino; Werner Stenzel
Journal:  Brain Pathol       Date:  2021-05       Impact factor: 6.508

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.